Q1 EPS Estimate for Sage Therapeutics Increased by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Investment analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued on Wednesday, November 20th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($1.31) per share for the quarter, up from their prior forecast of ($1.38). Wedbush has a “Neutral” rating and a $8.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.50) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.83) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.29) EPS.

SAGE has been the topic of several other research reports. Bank of America decreased their price target on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a report on Wednesday, October 9th. Truist Financial lowered their price target on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Oppenheimer cut their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, October 30th. StockNews.com downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Scotiabank cut their price target on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.83.

Sage Therapeutics Trading Up 6.6 %

Shares of Sage Therapeutics stock opened at $5.17 on Monday. The company’s 50-day moving average price is $6.70 and its 200-day moving average price is $9.02. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $28.26. The company has a market cap of $316.25 million, a price-to-earnings ratio of -0.93 and a beta of 0.92.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter in the previous year, the firm posted ($2.81) earnings per share. The business’s revenue for the quarter was up 337.1% compared to the same quarter last year.

Institutional Trading of Sage Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC raised its holdings in Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 2,782 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Sage Therapeutics during the first quarter valued at about $127,000. Virtu Financial LLC purchased a new stake in shares of Sage Therapeutics during the first quarter worth about $187,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares during the last quarter. Finally, Quest Partners LLC grew its stake in shares of Sage Therapeutics by 14.5% in the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after purchasing an additional 1,486 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.